Low level of Her-2 locus amplification by fluorescent in situ hybridization does not correlate with Her-2 protein overexpression by immunohistochemistry in Barrett's esophagus

Journal of Oncology

Volumn , Issue , 2010, Pages

  Krishnadath, Kausillia K ^a   Rygiel, Agnieszka M ^a   Milano, Francesca ^a   Ten Kate, Fiebo J ^a   Bergman, Jacques J G H M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CHROMOSOME 17; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE NUMBER; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE;

EID: 77954602405     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/382582     Document Type: Article

References (41)

1. Shaheen N. J., Advances in Barrett's esophagus and esophageal adenocarcinoma Gastroenterology 2005 128 6 1554 1566
2. O'Connor J. B., Falk G. W., Richter J. E., The incidence of adenocarcinoma and dysplasia in Barrett's esophagus report on the Cleveland Clinic Barrett's Esophagus Registry American Journal of Gastroenterology 1999 94 8 2037 2042
3. Devesa S. S., Blot W. J., Fraumeni J. F. Jr., Changing patterns in the incidence of esophageal and gastric carcinoma in the United States Cancer 1998 83 10 2049 2053
4. Peracchia A., Bonavina L., Via A., Incarbone R., Current trends in the surgical treatment of esophageal and cardia adenocarcinoma Journal of Experimental and Clinical Cancer Research 1999 18 3 289 294
5. Reid B. J., Haggitt R. C., Rubin C. E., Observer variation in the diagnosis of dysplasia in Barrett's esophagus Human Pathology 1988 19 2 166 178
6. Montgomery E., Bronner M. P., Goldblum J. R., Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation Human Pathology 2001 32 4 368 378
7. Mueller J., Werner M., Stolte M., Barrett's esophagus: histopathologic definitions and diagnostic criteria World Journal of Surgery 2004 28 2 148 154
8. Bianco A. R., Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications Journal of Chemotherapy 2004 16 4 52 54
9. Mnard S., Tagliabue E., Campiglio M., Pupa S. M., Role of HER2 gene overexpression in breast carcinoma Journal of Cellular Physiology 2000 182 2 150 162
10. Ross J. S., Fletcher J. A., The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy Stem Cells 1998 16 6 413 428
11. Tzahar E., Yarden Y., The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands Biochimica et Biophysica Acta 1998 1377 1 M25 M37
12. Slamon D. J., Leyland-Jones B., Shak S., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 The New England Journal of Medicine 2001 344 11 783 792
13. Romond E. H., Perez E. A., Bryant J., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer The New England Journal of Medicine 2005 353 16 1673 1684
14. Al-Kasspooles M., Moore J. H., Orringer M. B., Beer D. G., Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas International Journal of Cancer 1993 54 2 213 219
15. Jankowski J., Coghill G., Hopwood D., Wormsley K. G., Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus Gut 1992 33 8 1033 1038
16. Flejou J.-F., Paraf F., Muzeau F., Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations Journal of Clinical Pathology 1994 47 1 23 26
17. Kim R., Clarke M. R., Melhem M. F., Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma Digestive Diseases and Sciences 1997 42 12 2453 2462
18. Geddert H., Zeriouh M., Wolter M., Heise J. W., Gabbert H. E., Sarbia M., Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions American Journal of Clinical Pathology 2002 118 1 60 66
19. Walch A., Specht K., Bink K., Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia- adenocarcinoma sequence of Barrett's esophagus Laboratory Investigation 2001 81 6 791 801
20. Rossi E., Villanacci V., Bassotti G., Her-2/neu in Barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization Diagnostic Molecular Pathology 2006 15 3 125 130
21. Safran H., DiPetrillo T., Akerman P., Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma International Journal of Radiation Oncology Biology Physics 2007 67 2 405 409
22. Penault-Llorca F., Adelaide J., Houvenaeghel G., Hassoun J., Birnbaum D., Jacquemier J., Optimization of immunohistochemical detection of ERBB 2 in human breast cancer: impact of fixation Journal of Pathology 1994 173 1 65 75
23. Press M. F., Hung G., Godolphin W., Slamon D. J., Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression Cancer Research 1994 54 10 2771 2777
24. Persons D. L., Bui M. M., Lowery M. C., Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study Annals of Clinical and Laboratory Science 2000 30 1 41 48
25. Brien T. P., Odze R. D., Sheehan C. E., McKenna B. J., Ross J. S., Her-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma Human Pathology 2000 31 1 35 39
26. Brankley S. M., Wang K. K., Harwood A. R., The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus Journal of Molecular Diagnostics 2006 8 2 260 267
27. Rygiel A. M., van Baal J. W., Milano F., Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population Cancer 2007 109 10 1980 1988
28. Tbakhi A., Totos G., Hauser-Kronberger C., Fixation conditions for DNA and RNA in situ hybridization: a reassessment of molecular morphology dogma American Journal of Pathology 1998 152 1 35 41
29. Reid B. J., Blount P. L., Feng Z., Levine D. S., Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia American Journal of Gastroenterology 2000 95 11 3089 3096
30. Peters F. P., Krishnadath K. K., Rygiel A. M., Stepwise radical endoscopic resection of the complete Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities American Journal of Gastroenterology 2007 102 9 1853 1861
31. Walch A., Bink K., Gais P., Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma Analytical Cellular Pathology 2000 20 1 25 32
32. Couturier J., Vincent-Salomon A., Nicolas A., Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma Modern Pathology 2000 13 11 1238 1243
33. Dowsett M., Bartlett J., Ellis I. O., Correlation between immunohistochemistry (Hercep Test) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres Journal of Pathology 2003 199 4 418 423
34. Mayr D., Kanitz V., Amann G., HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays Histopathology 2006 48 2 149 156
35. Maley C. C., Galipeau P. C., Finley J. C., Genetic clonal diversity predicts progression to esophageal adenocarcinoma Nature Genetics 2006 38 4 468 473
36. Persons D. L., Borelli K. A., Hsu P. H., Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization Modern Pathology 1997 10 7 720 727
37. Kallioniemi O.-P., Kallioniemi A., Kurisu W., ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization Proceedings of the National Academy of Sciences of the United States of America 1992 89 12 5321 5325
38. Pauletti G., Godolphin W., Press M. F., Slamon D. J., Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization Oncogene 1996 13 1 63 72
39. Hammock L., Lewis M., Phillips C., Cohen C., Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization Human Pathology 2003 34 10 1043 1047
40. Hofmann M., Stoss O., Gaiser T., Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy Journal of Clinical Pathology 2008 61 1 89 94
41. Safran H., DiPetrillo T., Nadeem A., Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study Cancer Investigation 2004 22 5 670 677